Intensity of Oral Anticoagulation in Patients Monitored with Various Thromboplastins

Publisher Website
Google Scholar
Abstract
To the Editor: The report by Hull et al. (Dec. 30 issue)1 on the optimal therapeutic range in oral anticoagulant control is the first to indicate convincingly that prolongation of the prothrombin time to ratios of 2 to 2.5 times normal as assessed with Simplastin (a thromboplastin of rabbit origin widely used in the United States) represents gross overanticoagulation in patients with venous thrombosis. The conclusion is that aiming at a prolongation range as low as 1.35 to 1.5 with Simplastin still satisfactorily protects against recurrent venous thrombosis, with a minimum of bleeding.In Europe, where other thromboplastins are often . . .